Red blood cell clearance in inflammation

Transfusion Medicine and Hemotherapy

Volumn 39, Issue 5, 2012, Pages 353-360

  Straat, Marleen ^a   Van Bruggen, Robin ^b   De Korte, Dirk ^c   Juffermans, Nicole P ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b SANQUIN RESEARCH   (Netherlands)

^c CENTRAL LABORATORY   (Netherlands)

Author keywords

Erythrocyte clearance; Inflammation; Senescence

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CERAMIDE; ERYTHROPOIETIN; IRON; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHOSPHATIDYLSERINE; SPHINGOMYELIN PHOSPHODIESTERASE; TUMOR NECROSIS FACTOR ALPHA;

ANEMIA; BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING ORGAN SYSTEMS; BONE MARROW; CAPILLARY FLOW; CYTOKINE PRODUCTION; ENDOTHELIUM; ENZYME ACTIVITY; ERYTHROCYTE; ERYTHROCYTE CLEARANCE; ERYTHROPHAGOCYTOSIS; HUMAN; INFLAMMATION; PHAGOCYTOSIS; PROTEIN EXPRESSION; REVIEW; SEPSIS;

EID: 84867019430     PISSN: 16603796     EISSN: 16603818     Source Type: Journal    
DOI: 10.1159/000342229     Document Type: Review

References (118)

1. Rodriguez RM, Corwin HL, Gettinger A, Corwin MJ, Gubler D, Pearl RG: Nutritional deficiencies and blunted erythropoietin response as causes of the anemia of critical illness. J Crit Care 2001;16: 36-41.
2. Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Abraham E, MacIntyre NR, Shabot MM, Duh MS, Shapiro MJ: The CRIT Study: anemia and blood transfusion in the critically ill-current clinical practice in the United States. Crit Care Med 2004;32:39-52.
3. Croce MA, Tolley EA, Claridge JA, Fabian TC: Transfusions result in pulmonary morbidity and death after a moderate degree of injury. J Trauma 2005;59:19-23, discussion 23-14.
4. Gajic O, Rana R, Mendez JL, Rickman OB, Lymp JF, Hubmayr RD, Moore SB: Acute lung injury after blood transfusion in mechanically ventilated patients. Transfusion 2004;44:1468-1474.
5. Gong MN, Thompson BT, Williams P, Pothier L, Boyce PD, Christiani DC: Clinical predictors of and mortality in acute respiratory distress syndrome: potential role of red cell transfusion. Crit Care Med 2005;33:1191-1198.
6. Vamvakas EC: Pneumonia as a complication of blood product transfusion in the critically ill: transfusion-related immunomodulation (TRIM). Crit Care Med 2006;34:S151-159.
7. Aird WC: The hematologic system as a marker of organ dysfunction in sepsis. Mayo Clin Proc 2003; 78:869-881.
8. Von Ahsen N, Muller C, Serke S, Frei U, Eckardt KU: Important role of nondiagnostic blood loss and blunted erythropoietic response in the anemia of medical intensive care patients. Crit Care Med 1999;27:2630-2639.
9. Weisbach V, Corbiere C, Strasser E, Zingsem J, Zimmermann R, Eckstein R: The variability of compensatory erythropoiesis in repeated autologous blood donation. Transfusion 2001;41:179-183.
10. Hansen NE: The anaemia of chronic disorders. A bag of unsolved questions. Scand J Haematol 1983; 31:397-402.
11. Rogiers P, Zhang H, Leeman M, Nagler J, Neels H, Melot C, Vincent JL: Erythropoietin response is blunted in critically ill patients. Intensive Care Med 1997;23:159-162.
12. Van Iperen CE, Gaillard CA, Kraaijenhagen RJ, Braam BG, Marx JJ, van de Wiel A: Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients. Crit Care Med 2000;28:2773-2778.
13. Corwin HL, Gettinger A, Fabian TC, May A, Pearl RG, Heard S, An R, Bowers PJ, Burton P, Klausner MA, Corwin MJ: Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 2007;357: 965-976.
14. DeAngelo AJ, Bell DG, Quinn MW, Long DE, Ouellette DR: Erythropoietin response in critically ill mechanically ventilated patients: a prospective observational study. Crit Care 2005;9:R172-176.
15. Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Shapiro MJ, Corwin MJ, Colton T: Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA 2002;288:2827-2835.
16. Zarychanski R, Turgeon AF, McIntyre L, Fergusson DA: Erythropoietin- receptor agonists in critically ill patients: a meta-analysis of randomized controlled trials. CMAJ 2007;177:725-734.
17. Claessens YE, Fontenay M, Pene F, Chiche JD, Guesnu M, Hababou C, Casadevall N, Dhainaut JF, Mira JP, Cariou A: Erythropoiesis abnormalities contribute to early-onset anemia in patients with septic shock. Am J Respir Crit Care Med 2006;174:51-57.
18. Georgopoulos D, Matamis D, Routsi C, Michalopoulos A, Maggina N, Dimopoulos G, Zakynthinos E, Nakos G, Thomopoulos G, Mandragos K, Maniatis A: Recombinant human erythropoietin therapy in critically ill patients: a dose-response study (ISRCTN48523317). Crit Care 2005;9:R508-515.
19. Kemna E, Pickkers P, Nemeth E, van der Hoeven H, Swinkels D: Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood 2005;106:1864-1866.
20. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T: Il-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004;113:1271-1276.
21. Sihler KC, Raghavendran K, Westerman M, Ye W, Napolitano LM: Hepcidin in trauma: linking injury, inflammation, and anemia. J Trauma 2010;69:831-837.
22. Lasocki S, Baron G, Driss F, Westerman M, Puy H, Boutron I, Beaumont C, Montravers P: Diagnostic accuracy of serum hepcidin for iron deficiency in critically ill patients with anemia. Intensive Care Med 2010;36:1044-1048.
23. Foller M, Huber SM, Lang F: Erythrocyte programmed cell death. IUBMB Life 2008;60:661-668.
24. Lang KS, Lang PA, Bauer C, Duranton C, Wieder T, Huber SM, Lang F: Mechanisms of suicidal erythrocyte death. Cell Physiol Biochem 2005;15: 195-202.
25. Lang F, Qadri SM: Mechanisms and significance of eryptosis, the suicidal death of erythrocytes. Blood Purif 2012;33:125-130.
26. Boas FE, Forman L, Beutler E: Phosphatidylserine exposure and red cell viability in red cell aging and in hemolytic anemia. Proc Natl Acad Sci USA 1998;95:3077-3081.
27. Fadok VA, Bratton DL, Rose DM, Pearson A, Ezekewitz RA, Henson PM: A receptor for phosphatidylserine-specific clearance of apoptotic cells. Nature 2000;405:85-90.
28. Li MO, Sarkisian MR, Mehal WZ, Rakic P, Flavell RA: Phosphatidylserine receptor is required for clearance of apoptotic cells. Science 2003;302:1560-1563.
29. Park SY, Jung MY, Kim HJ, Lee SJ, Kim SY, Lee BH, Kwon TH, Park RW, Kim IS: Rapid cell corpse clearance by stabilin-2, a membrane phosphatidylserine receptor. Cell Death Differ 2008;15:192-201.
30. Kobayashi N, Karisola P, Pena-Cruz V, Dorfman DM, Jinushi M, Umetsu SE, Butte MJ, Nagumo H, Chernova I, Zhu B, Sharpe AH, Ito S, Dranoff G, Kaplan GG, Casasnovas JM, Umetsu DT, Dekruyff RH, Freeman GJ: TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells. Immunity 2007;27:927-940.
31. Raymond A, Ensslin MA, Shur BD: SED1/MFGE8: A bi-motif protein that orchestrates diverse cellular interactions. J Cell Biochem 2009;106:957-966.
32. Kay MM, Goodman SR, Sorensen K, Whitfield CF, Wong P, Zaki L, Rudloff V: Senescent cell antigen is immunologically related to band 3. Proc Natl Acad Sci USA 1983;80:1631-1635.
33. Zhang D, Kiyatkin A, Bolin JT, Low PS: Crystallographic structure and functional interpretation of the cytoplasmic domain of erythrocyte membrane band 3. Blood 2000;96:2925-2933.
34. Pantaleo A, Giribaldi G, Mannu F, Arese P, Turrini F: Naturally occurring anti-band 3 antibodies and red blood cell removal under physiological and pathological conditions. Autoimmun Rev 2008;7: 457-462.
35. Low PS: Structure and function of the cytoplasmic domain of band 3: center of erythrocyte membrane-peripheral protein interactions. Biochim Bio phys Acta 1986;864:145-167.
36. Hornig R, Lutz HU: Band 3 protein clustering on human erythrocytes promotes binding of naturally occurring anti-band 3 and anti-spectrin antibodies. Exp Gerontol 2000;35:1025-1044.
37. Arese P, Turrini F, Schwarzer E: Band 3/complement-mediated recognition and removal of normally senescent and pathological human erythrocytes. Cell Physiol Biochem 2005;16:133-146.
38. Mannu F, Arese P, Cappellini MD, Fiorelli G, Cappadoro M, Giribaldi G, Turrini F: Role of hemichrome binding to erythrocyte membrane in the generation of band-3 alterations in beta-thalassemia intermedia erythrocytes. Blood 1995;86:2014-2020.
39. Waugh SM, Willardson BM, Kannan R, Labotka RJ, Low PS: Heinz bodies induce clustering of band 3, glycophorin, and ankyrin in sickle cell erythrocytes. J Clin Invest 1986;78:1155-1160.
40. Ayi K, Turrini F, Piga A, Arese P: Enhanced phagocytosis of ring-parasitized mutant erythrocytes: a common mechanism that may explain protection against falciparum malaria in sickle trait and beta-thalassemia trait. Blood 2004;104:3364-3371.
41. Cappellini MD, Tavazzi D, Duca L, Graziadei G, Mannu F, Turrini F, Arese P, Fiorelli G: Metabolic indicators of oxidative stress correlate with haemichrome attachment to membrane, band 3 aggregation and erythrophagocytosis in beta-thalassaemia intermedia. Br J Haematol 1999;104:504-512.
42. Kay MM: Posttranslational changes in band 3 in aging and Alzheimer's disease: do anion and glucose transport changes reflect or foreshadow the eventual metabolic abnormalities? Cell Mol Biol (Noisy-le-grand) 1998;44:271-272.
43. Kay MM: Band 3 and its alterations in health and disease. Cell Mol Biol (Noisy-le-grand) 2004;50: 117-138.
44. Lutz HU, Bussolino F, Flepp R, Fasler S, Stammler P, Kazatchkine MD, Arese P: Naturally occurring anti-band-3 antibodies and complement together mediate phagocytosis of oxidatively stressed human erythrocytes. Proc Natl Acad Sci USA 1987;84:7368-7372.
45. Lutz HU, Nater M, Stammler P: Naturally occurring anti-band 3 antibodies have a unique affinity for C3. Immunology 1993;80:191-196.
46. Lutz HU, Jelezarova E: Complement amplification revisited. Mol Immunol 2006;43:2-12.
47. Fries LF, Siwik SA, Malbran A, Frank MM: Phagocytosis of target particles bearing C3b-IgG covalent complexes by human monocytes and polymorphonuclear leucocytes. Immunology 1987;62:45-51.
48. Oldenborg PA, Zheleznyak A, Fang YF, Lagenaur CF, Gresham HD, Lindberg FP: Role of CD47 as a marker of self on red blood cells. Science 2000; 288:2051-2054.
49. Oldenborg PA, Gresham HD, Lindberg FP: CD47-signal regulatory protein alpha (SIRPα) regulates Fcgamma and complement receptor-mediated phagocytosis. J Exp Med 2001;193:855-862.
50. Olsson M, Nilsson A, Oldenborg PA: Dose-dependent inhibitory effect of CD47 in macrophage uptake of IgG-opsonized murine erythrocytes. Biochem Biophys Res Commun 2007;352:193-197.
51. Olsson M, Oldenborg PA: CD47 on experimentally senescent murine RBCs inhibits phagocytosis following Fcgamma receptor-mediated but not scavenger receptor-mediated recognition by macrophages. Blood 2008;112:4259-4267.
52. Tsai RK, Rodriguez PL, Discher DE: Self inhibition of phagocytosis: The affinity of 'marker of self' CD47 for SIRPα dictates potency of inhibition but only at low expression levels. Blood Cells Mol Dis 2010;45:67-74.
53. Burger P, Hilarius-Stokman P, de Korte D, van den Berg TK, van Bruggen R: CD47 functions as a molecular switch for erythrocyte phagocytosis. Blood 2012
54. Matozaki T, Murata Y, Okazawa H, Ohnishi H: Functions and molecular mechanisms of the CD47-SIRPα signalling pathway. Trends Cell Biol 2009;19:72-80.
55. Sato R, Ohnishi H, Kobayashi H, Kiuchi D, Hayashi A, Kaneko Y, Honma N, Okazawa H, Hirata Y, Matozaki T: Regulation of multiple functions of SHPS-1, a transmembrane glycoprotein, by its cytoplasmic region. Biochem Biophys Res Commun 2003;309:584-590.
56. Ishikawa-Sekigami T, Kaneko Y, Okazawa H, Tomizawa T, Okajo J, Saito Y, Okuzawa C, Sugawara-Yokoo M, Nishiyama U, Ohnishi H, Matozaki T, Nojima Y: SHPS-1 promotes the survival of circulating erythrocytes through inhibition of phagocytosis by splenic macrophages. Blood 2006;107:341-348.
57. Babic I, Schallhorn A, Lindberg FP, Jirik FR: SHPS-1 induces aggregation of Ba/F3 pro-B cells via an interaction with CD47. J Immunol 2000;164: 3652-3658.
58. Tada K, Tanaka M, Hanayama R, Miwa K, Shinohara A, Iwamatsu A, Nagata S: Tethering of apoptotic cells to phagocytes through binding of CD47 to SRC homology 2 domain-bearing protein tyrosine phosphatase substrate-1. J Immunol 2003;171: 5718-5726.
59. Bornstein P: Thrombospondins as matricellular modulators of cell function. J Clin Invest 2001; 107:929-934.
60. Carlson CB, Lawler J, Mosher DF: Structures of thrombospondins. Cell Mol Life Sci 2008;65:672-686.
61. Piagnerelli M, Boudjeltia KZ, Vanhaeverbeek M, Vincent JL: Red blood cell rheology in sepsis. Intensive Care Med 2003;29:1052-1061.
62. Piagnerelli M, Cotton F, Van Nuffelen M, Vincent JL, Gulbis B: Modifications in erythrocyte membrane protein content are not responsible for the alterations in rheology seen in sepsis. Shock 2012; 37:17-21.
63. Mebius RE, Kraal G: Structure and function of the spleen. Nat Rev Immunol 2005;5:606-616.
64. Bratosin D, Mazurier J, Tissier JP, Estaquier J, Huart JJ, Ameisen JC, Aminoff D, Montreuil J: Cellular and molecular mechanisms of senescent erythrocyte phagocytosis by macrophages. A review. Biochimie 1998;80:173-195.
65. Dondorp AM, Chotivanich KT, Fucharoen S, Silamut K, Vreeken J, Kager PA, White NJ: Red cell deformability, splenic function and anaemia in thalassaemia. Br J Haematol 1999;105:505-508.
66. Deplaine G, Safeukui I, Jeddi F, Lacoste F, Brousse V, Perrot S, Biligui S, Guillotte M, Guitton C, Dokmak S, Aussilhou B, Sauvanet A, Cazals Hatem D, Paye F, Thellier M, Mazier D, Milon G, Mohandas N, Mercereau-Puijalon O, David PH, Buffet PA: The sensing of poorly deformable red blood cells by the human spleen can be mimicked in vitro. Blood 2011;117:e88-95.
67. Barabino GA, Platt MO, Kaul DK: Sickle cell biomechanics. Annu Rev Biomed Eng 2010;12:345-367.
68. Betticher DC, Keller H, Maly FE, Reinhart WH: The effect of endotoxin and tumour necrosis factor on erythrocyte and leucocyte deformability in vitro. Br J Haematol 1993;83:130-137.
69. Astiz ME, DeGent GE, Lin RY, Rackow EC: Microvascular function and rheologic changes in hyperdynamic sepsis. Crit Care Med 1995;23:265-271.
70. Baskurt OK, Gelmont D, Meiselman HJ: Red blood cell deformability in sepsis. Am J Respir Crit Care Med 1998;157:421-427.
71. Kirschenbaum LA, Aziz M, Astiz ME, Saha DC, Rackow EC: Influence of rheologic changes and platelet-neutrophil interactions on cell filtration in sepsis. Am J Respir Crit Care Med 2000;161:1602-1607.
72. Poschl JM, Ruef P, Schnauffer M, Pohl S, Sonntag HG, Linderkamp O: Group B streptococcus impairs erythrocyte deformability in neonates more than in adults. Arch Dis Child Fetal Neonatal Ed 1996;74:F187-190.
73. Powell RJ, Machiedo GW, Rush BF Jr, Dikdan G: Oxygen free radicals: effect on red cell deformability in sepsis. Crit Care Med 1991;19:732-735.
74. Huwiler A, Kolter T, Pfeilschifter J, Sandhoff K: Physiology and pathophysiology of sphingolipid metabolism and signaling. Biochim Biophys Acta 2000;1485:63-99.
75. Lang KS, Myssina S, Brand V, Sandu C, Lang PA, Berchtold S, Huber SM, Lang F, Wieder T: Involvement of ceramide in hyperosmotic shock-induced death of erythrocytes. Cell Death Differ 2004;11:231-243.
76. Jenkins RW, Canals D, Hannun YA: Roles and regulation of secretory and lysosomal acid sphingomyelinase. Cell Signal 2009;21:836-846.
77. Chatterjee S: Neutral sphingomyelinase: past, present and future. Chem Phys Lipids 1999;102: 79-96.
78. Lang PA, Kempe DS, Tanneur V, Eisele K, Klarl BA, Myssina S, Jendrossek V, Ishii S, Shimizu T, Waidmann M, Hessler G, Huber SM, Lang F, Wieder T: Stimulation of erythrocyte ceramide formation by platelet-activating factor. J Cell Sci 2005;118:1233-1243.
79. Kempe DS, Akel A, Lang PA, Hermle T, Biswas R, Muresanu J, Friedrich B, Dreischer P, Wolz C, Schumacher U, Peschel A, Gotz F, Doring G, Wieder T, Gulbins E, Lang F: Suicidal erythrocyte death in sepsis. J Mol Med 2007;85:273-281.
80. Spolarics Z, Condon MR, Siddiqi M, Machiedo GW, Deitch EA: Red blood cell dysfunction in septic glucose-6-phosphate dehydrogenase-deficient mice. Am J Physiol Heart Circ Physiol 2004; 286:H2118-2126.
81. Condon MR, Feketova E, Machiedo GW, Deitch EA, Spolarics Z: Augmented erythrocyte band-3 phosphorylation in septic mice. Biochim Biophys Acta 2007;1772:580-586.
82. Saldanha C, Silva AS, Goncalves S, Martins-Silva J: Modulation of erythrocyte hemorheological properties by band 3 phosphorylation and dephosphorylation. Clin Hemorheol Microcirc 2007;36:183-194.
83. de Almeida JP, Freitas-Santos T, Saldanha C: Erythrocyte deformability dependence on band 3 protein in an in-vitro model of hyperfibrinogenemia. Clin Hemorheol Microcirc 2011
84. Davies KJ, Goldberg AL: Oxygen radicals stimulate intracellular proteolysis and lipid peroxidation by independent mechanisms in erythrocytes. J Biol Chem 1987;262:8220-8226.
85. Uyesaka N, Hasegawa S, Ishioka N, Ishioka R, Shio H, Schechter AN: Effects of superoxide anions on red cell deformability and membrane proteins. Biorheology 1992;29:217-229.
86. Srour, Bilto YY, Juma M, Irhimeh MR: Exposure of human erythrocytes to oxygen radicals causes loss of deformability, increased osmotic fragility, lipid peroxidation and protein degradation. Clin Hemorheol Microcirc 2000;23:13-21.
87. Bhagat K, Vallance P: Nitric oxide 9 years on. J R Soc Med 1996;89:667-673.
88. Lloyd-Jones DM, Bloch KD: The vascular biology of nitric oxide and its role in atherogenesis. Annu Rev Med 1996;47:365-375.
89. Marin J, Rodriguez-Martinez MA: Role of vascular nitric oxide in physiological and pathological conditions. Pharmacol Ther 1997;75:111-134.
90. Eiserich JP, Patel RP, O'Donnell VB: Pathophysiology of nitric oxide and related species: free radical reactions and modification of biomolecules. Mol Aspects Med 1998;19:221-357.
91. Korbut R, Gryglewski RJ: Nitric oxide from polymorphonuclear leukocytes modulates red blood cell deformability in vitro. Eur J Pharmacol 1993; 234:17-22.
92. Mesquita R, Picarra B, Saldanha C, Martins e Silva J: Nitric oxide effects on human erythrocytes structural and functional properties-an in vitro study. Clin Hemorheol Microcirc 2002;27:137-147.
93. Ismail NH, Cohn EJ Jr, Mollitt DL: Nitric oxide synthase inhibition negates septic-induced alterations in cytoplasmic calcium homeostasis and membrane dynamics. Am Surg 1997;63:20-23.
94. Bateman RM, Jagger JE, Sharpe MD, Ellsworth ML, Mehta S, Ellis CG: Erythrocyte deformability is a nitric oxide-mediated factor in decreased capillary density during sepsis. Am J Physiol Heart Circ Physiol 2001;280:H2848-2856.
95. Mohandas N, Gallagher PG: Red cell membrane: past, present, and future. Blood 2008;112:3939-3948.
96. Grebe R, Wolff H, Schmid-Schonbein H: Influence of red cell surface charge on red cell membrane curvature. Pflugers Arch 1988;413:77-82.
97. Piagnerelli M, Boudjeltia KZ, Brohee D, Piro P, Carlier E, Vincent JL, Lejeune P, Vanhaeverbeek M: Alterations of red blood cell shape and sialic acid membrane content in septic patients. Crit Care Med 2003;31:2156-2162.
98. Kanoore Edul VS, Enrico C, Laviolle B, Risso Vazquez A, Ince C, Dubin A: Quantitative assessment of the microcirculation in healthy volunteers and in patients with septic shock. Crit Care Med 2012;40:1443-1448.
99. De Backer D, Creteur J, Preiser JC, Dubois MJ, Vincent JL: Microvascular blood flow is altered in patients with sepsis. Am J Respir Crit Care Med 2002;166:98-104.
100. Trzeciak S, Dellinger RP, Parrillo JE, Guglielmi M, Bajaj J, Abate NL, Arnold RC, Colilla S, Zanotti S, Hollenberg SM: Early microcirculatory perfusion derangements in patients with severe sepsis and septic shock: relationship to hemodynamics, oxygen transport, and survival. Ann Emerg Med 2007;49:88-98, 98.e81-82.
101. Sakr Y, Dubois MJ, De Backer D, Creteur J, Vincent JL: Persistent microcirculatory alterations are associated with organ failure and death in patients with septic shock. Crit Care Med 2004;32: 1825-1831.
102. Boerma EC, Koopmans M, Konijn A, Kaiferova K, Bakker AJ, van Roon EN, Buter H, Bruins N, Egbers PH, Gerritsen RT, Koetsier PM, Kingma WP, Kuiper MA, Ince C: Effects of nitroglycerin on sublingual microcirculatory blood flow in patients with severe sepsis/septic shock after a strict resuscitation protocol: a double-blind randomized placebo controlled trial. Crit Care Med 2010;38: 93-100.
103. De Backer D, Creteur J, Dubois MJ, Sakr Y, Koch M, Verdant C, Vincent JL: The effects of dobutamine on microcirculatory alterations in patients with septic shock are independent of its systemic effects. Crit Care Med 2006;34:403-408.
104. Zeerleder S, Hack CE, Wuillemin WA: Disseminated intravascular coagulation in sepsis. Chest 2005;128:2864-2875.
105. Eichelbronner O, Sielenkamper A, Cepinskas G, Sibbald WJ, Chin-Yee IH: Endotoxin promotes adhesion of human erythrocytes to human vascular endothelial cells under conditions of flow. Crit Care Med 2000;28:1865-1870.
106. Anniss AM, Sparrow RL: Variable adhesion of different red blood cell products to activated vascular endothelium under flow conditions. Am J Hematol 2007;82:439-445.
107. Shiu YT, McIntire LV: In vitro studies of erythrocyte-vascular endothelium interactions. Ann Biomed Eng 2003;31:1299-1313.
108. Cohen MJ, Brohi K, Calfee CS, Rahn P, Chesebro BB, Christiaans SC, Carles M, Howard M, Pittet JF: Early release of high mobility group box nuclear protein 1 after severe trauma in humans: role of injury severity and tissue hypoperfusion. Crit Care 2009;13:R174.
109. Mangalmurti NS, Chatterjee S, Cheng G, Andersen E, Mohammed A, Siegel DL, Schmidt AM, Albelda SM, Lee JS: Advanced glycation end products on stored red blood cells increase endothelial reactive oxygen species generation through interaction with receptor for advanced glycation end products. Transfusion 2010;50: 2353-2361.
110. Closse C, Dachary-Prigent J, Boisseau MR: Phosphatidylserine-related adhesion of human erythrocytes to vascular endothelium. Br J Haematol 1999;107:300-302.
111. Chung SM, Bae ON, Lim KM, Noh JY, Lee MY, Jung YS, Chung JH: Lysophosphatidic acid induces thrombogenic activity through phosphatidylserine exposure and procoagulant microvesicle generation in human erythrocytes. Arterioscler Thromb Vasc Biol 2007;27:414-421.
112. Andrews DA, Low PS: Role of red blood cells in thrombosis. Curr Opin Hematol 1999;6:76-82.
113. Gallagher PG, Chang SH, Rettig MP, Neely JE, Hillery CA, Smith BD, Low PS: Altered erythrocyte endothelial adherence and membrane phospholipid asymmetry in hereditary hydrocytosis. Blood 2003;101:4625-4627.
114. Pandolfi A, Di Pietro N, Sirolli V, Giardinelli A, Di Silvestre S, Amoroso L, Di Tomo P, Capani F, Consoli A, Bonomini M: Mechanisms of uremic erythrocyte-induced adhesion of human monocytes to cultured endothelial cells. J Cell Physiol 2007;213:699-709.
115. Wood BL, Gibson DF, Tait JF: Increased erythrocyte phosphatidylserine exposure in sickle cell disease: Flow-cytometric measurement and clinical associations. Blood 1996;88:1873-1880.
116. Zwaal RF, Comfurius P, Bevers EM: Surface exposure of phosphatidylserine in pathological cells. Cell Mol Life Sci 2005;62:971-988.
117. Eichelbronner O, Sibbald WJ, Chin-Yee IH: Intermittent flow increases endotoxin-induced adhesion of human erythrocytes to vascular endothelial cells. Intensive Care Med 2003;29:709-714.
118. Burger P, de Korte D, van den Berg TK, van Bruggen R: CD47 in Erythrocyte Ageing and Clearance-the Dutch point of view. Transfus Med Hemother 2012;39(5): DOI: 10.1159/000342231.